Consistently, it has been recognized that CXCL3 and its receptor CXCR2 were highly expressed in hepatocellular carcinoma, esophageal cancer, and invasive breast cancer [13–15], and CXCL3/CXCR2-mediated signaling was crucial for the variation in the expression of numerous tumor-related genes, which is an essential event that is extremely implicated in tumor progression [16]. The gene discussed is CXCL3; the disease is esophageal cancer.